Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Christensen

Showing results (471-480 of 510) with videos related to

Pageof 51
Sort By:
Journal of Medicinal Chemistry|December 29, 2023
Discovery of Five SOS2 Fragment Hits with Binding Modes Determined by SOS2 X-Ray CocrystallographyChristopher R Smith, Dan Chen, James G Christensen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2025
Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 TrialMarcelo V Negrao, Alvaro G Paula, David Molkentine, et al.
The Journal of Antibiotics|January 27, 2009
Exploring the positional attachment of glycopeptide/beta-lactam heterodimersDaniel D Long, James B Aggen, Jason Chinn, et al.
The Journal of Antibiotics|August 12, 2004
Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424)Michael R Leadbetter, Stacy M Adams, Bettina Bazzini, et al.
European Journal of Cancer (Oxford, England : 1990)|September 10, 2013
Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitorsKaren E Sheppard, Carleen Cullinane, Katherine M Hannan, et al.
Nature Medicine|June 12, 2012
Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemiaAlex Kentsis, Casie Reed, Kim L Rice, et al.
The Journal of Clinical Investigation|January 5, 2012
An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in miceKathryn M Kinross, Karen G Montgomery, Margarete Kleinschmidt, et al.
Molecular Cancer Therapeutics|April 1, 2010
PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapyJitesh P Jani, Joel Arcari, Vincent Bernardo, et al.
Oncogene|November 19, 2008
Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivityZ Tang, S Jiang, R Du, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationshipDirk B Mendel, A Douglas Laird, Xiaohua Xin, et al.
Pageof 51

Showing results (471-480 of 510) with videos related to

Sort By:
Pageof 51
Journal of Medicinal Chemistry|December 29, 2023
Discovery of Five SOS2 Fragment Hits with Binding Modes Determined by SOS2 X-Ray CocrystallographyChristopher R Smith, Dan Chen, James G Christensen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2025
Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 TrialMarcelo V Negrao, Alvaro G Paula, David Molkentine, et al.
The Journal of Antibiotics|January 27, 2009
Exploring the positional attachment of glycopeptide/beta-lactam heterodimersDaniel D Long, James B Aggen, Jason Chinn, et al.
The Journal of Antibiotics|August 12, 2004
Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424)Michael R Leadbetter, Stacy M Adams, Bettina Bazzini, et al.
European Journal of Cancer (Oxford, England : 1990)|September 10, 2013
Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitorsKaren E Sheppard, Carleen Cullinane, Katherine M Hannan, et al.
Nature Medicine|June 12, 2012
Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemiaAlex Kentsis, Casie Reed, Kim L Rice, et al.
The Journal of Clinical Investigation|January 5, 2012
An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in miceKathryn M Kinross, Karen G Montgomery, Margarete Kleinschmidt, et al.
Molecular Cancer Therapeutics|April 1, 2010
PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapyJitesh P Jani, Joel Arcari, Vincent Bernardo, et al.
Oncogene|November 19, 2008
Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivityZ Tang, S Jiang, R Du, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationshipDirk B Mendel, A Douglas Laird, Xiaohua Xin, et al.
Pageof 51